Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.41 |
| ▸ | TTK | P33981 | 10/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279676 | 0.85 | MAPKAPK5 (0.59) | MAPK8FLT3MAPKAPK5ADORA3TTK | |
| SCHEMBL275077 | 0.85 | MAPKAPK5 (0.59) | MAPK8FLT3MAPKAPK5ADORA3TTK | |
| SCHEMBL279474 | 0.84 | MAPKAPK5 (0.60) | MAPK8FLT3MAPKAPK5ADORA3TTK | |
| SCHEMBL275912 | 0.82 | MAPKAPK5 (0.60) | MAPK8FLT3MAPKAPK5ADORA3TTK | |
| SCHEMBL27359923 | 0.81 | ADORA3 (0.51) | MAPK8FLT3ADORA3TTK | |
| SCHEMBL279439 | 0.79 | MAPKAPK5 (0.62) | FLT3MAPKAPK5TTK | |
| SCHEMBL275076 | 0.79 | FLT3 (0.42) | MAPK8FLT3MAPKAPK5ADORA3TTK | |
| SCHEMBL275911 | 0.76 | FLT3 (0.43) | MAPK8FLT3MAPKAPK5ADORA3TTK | |
| SCHEMBL27359187 | 0.75 | FLT3 (0.48) | MAPK8FLT3ADORA3TTK | |
| SCHEMBL275206 | 0.74 | MAPK8 (0.54) | MAPK8FLT3ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138193-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-20 | — | — | US | disclosed |
| US-20100240666-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240666-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | RRP15, RARS2, RO60 | MAPK8 3604/4885FLT3 1384/4885MAPKAPK5 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.